论文部分内容阅读
FDA批准Florbetapir F18注射液用于评估阿尔茨海默病和其他原因发生的认知障碍。此制剂是礼来公司开发的含氟-18的β-淀粉样蛋白显像剂,药物与阿尔茨海默病标志淀粉样蛋白斑块结合,用正电子发射断层扫描对脑显像。3次临床试验评价了此剂的效果。对所有阅片结果和活检患者结果比较,此剂的正电子
FDA approved Florbetapir F18 injection to assess cognitive impairment in Alzheimer’s disease and other causes. This formulation is a fluorine-18 beta-amyloid imaging agent developed by Eli Lilly and Company that binds to Alzheimer’s disease-identified amyloid plaques and uses positron emission tomography to visualize the brain. Three clinical trials evaluated the effect of this agent. The positron of this reagent is compared to the results of all readings and biopsies